ArticleEJNMMI research2020
Preclinical comparison of four [
Article in EJNMMI research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 49 citations in OpenAlex.
- True-PositiveJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Trial
- Chimeric peptide-based radiopharmaceuticals for glioblastoma imaging and therapy by targeting mHsp70 and enhancing BBB penetration.Chemical science · 2026Article
- Value of a repeatEuropean journal of nuclear medicine and molecular imaging · 2026Article
- AI lesion tracking in PET/CT imaging: a proposal for a Siamese-based CNN pipeline applied to PSMA PET/CT scans.European journal of nuclear medicine and molecular imaging · 2025Article
- Revolutionizing Prostate Cancer Detection: The Role of Approved PSMA-PET Imaging Agents.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Enhancing the radionuclide theranostic concept through the radiohybrid approach.RSC medicinal chemistry · 2025Review
- Biochemical failure-free survival ofScientific reports · 2025Article
- [Biomarker insights · 2025Article
- Significant reduction of activity retention in the kidneys via optimized linker sequences in radiohybrid-based minigastrin analogs.EJNMMI research · 2024Article
- Preclinical comparison of [EJNMMI radiopharmacy and chemistry · 2024Article
- Normal-organ distribution of PSMA-targeting PET radiopharmaceuticalAmerican journal of nuclear medicine and molecular imaging · 2024Article
- Medicinal (Radio) Chemistry: Building Radiopharmaceuticals for the Future.Current medicinal chemistry · 2024Review
- Flotufolastat F 18: Diagnostic First Approval.Molecular diagnosis & therapy · 2023Review
- Diagnostic Performance and Safety ofThe Journal of urology · 2023Article
- Synthesis and preclinical evaluation of novelEJNMMI research · 2023Article
- Validation ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Synthesis and Preclinical Evaluation ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Pretherapeutic Comparative Dosimetry ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Preclinical biodistribution and dosimetry and human biodistribution comparingEJNMMI research · 2022Article
- Radiolabeled PSMA Inhibitors.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
introductionRadiohybrid (rh) ligands, a novel class of prostate-specific membrane antigen (PSMA)-targeted radiopharmaceuticals, can be labeled either with [
aimSince [
methodsA synthetic protocol for enantiopure [
resultsCell studies revealed high PSMA affinity and internalization for [
conclusion[
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.